Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 15, 2025
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol,Metformin,Warfarin Sodium,BGM0504
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Overweight or Obese Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Paracetamol,Metformin,Warfarin Sodium,BGM0504
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Participants With Obesity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 04, 2025
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : BrightGene New Bio-Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : BrightGene New Bio-Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : BrightGene New Bio-Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Participants with Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : BGM0504,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : BrightGene New Bio-Medical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable